Chiltern, a global contract research organisation (CRO) headquartered in Slough, Berkshire, UK, is expanding its clinical development services in endocrinology and metabolism with the appointment of Randy Anderson as Senior Vice President of Scientific Affairs.
With nearly 30 years of industry experience, Anderson is an expert in diabetes and other endocrine/metabolism disorders. A board director for JDRF International, he also serves on multiple scientific advisory boards for pharmaceutical companies with endocrine products.
He joins Chiltern after 18 years with another major clinical research organisation, where he provided scientific leadership for the endocrinology and metabolism therapeutic area and was a key contributor on hundreds of trials and products. In addition to being the therapeutic area leader for endocrinology and metabolism, Anderson will become Chiltern’s administrative leader for its other scientific affairs experts across all therapeutic areas.
